Vanguard Group
XENE icon

Vanguard Group’s Xenon Pharmaceuticals XENE Stock Holding History

Vanguard Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$29.8M Sell
664,641
-186,745
-22% -$7.84M ﹤0.01% 2437
2025
Q3 		$34.2M Sell
851,386
-21,842
-3% -$769K ﹤0.01% 2345
2025
Q2 		$27.3M Buy
873,228
+536,714
+159% +$17.5M ﹤0.01% 2405
2025
Q1 		$11.3M Sell
336,514
-6,265
-2% -$238K ﹤0.01% 2777
2024
Q4 		$13.4M Sell
342,779
-1,586
-0.5% -$65.6K ﹤0.01% 2789
2024
Q3 		$13.6M Buy
344,365
+3,213
+0.9% +$130K ﹤0.01% 2803
2024
Q2 		$13.3M Buy
341,152
+5,517
+2% +$221K ﹤0.01% 2764
2024
Q1 		$14.4M Buy
335,635
+12,140
+4% +$558K ﹤0.01% 2761
2023
Q4 		$14.9M Buy
323,495
+56,669
+21% +$2M ﹤0.01% 2728
2023
Q3 		$9.11M Buy
266,826
+5,473
+2% +$205K ﹤0.01% 2937
2023
Q2 		$10.1M Buy
261,353
+11,999
+5% +$477K ﹤0.01% 2940
2023
Q1 		$8.92M Buy
249,354
+57,278
+30% +$2.12M ﹤0.01% 2995
2022
Q4 		$7.57M Buy
192,076
+6,884
+4% +$251K ﹤0.01% 3086
2022
Q3 		$6.69M Buy
185,192
+1,347
+0.7% +$48.4K ﹤0.01% 3158
2022
Q2 		$5.59M Buy
183,845
+20,377
+12% +$616K ﹤0.01% 3321
2022
Q1 		$5M Buy
163,468
+10,102
+7% +$302K ﹤0.01% 3529
2021
Q4 		$4.79M Buy
153,366
+46,174
+43% +$1.38M ﹤0.01% 3637
2021
Q3 		$1.64M Buy
107,192
+3,756
+4% +$65.3K ﹤0.01% 4121
2021
Q2 		$1.93M Sell
103,436
-3,359
-3% -$61.9K ﹤0.01% 3972
2021
Q1 		$1.91M Buy
106,795
+9,232
+9% +$156K ﹤0.01% 3871
2020
Q4 		$1.5M Buy
97,563
+2,670
+3% +$31.2K ﹤0.01% 3728
2020
Q3 		$1.05M Buy
94,893
+150
+0.2% +$1.76K ﹤0.01% 3648
2020
Q2 		$1.19M Buy
+94,743
New +$1.21M ﹤0.01% 3569

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group's XENE Position: Q4 2025 in Review

Vanguard Group reduced its Xenon Pharmaceuticals (XENE) stake by 22% in Q4 2025, selling an estimated $7.84M and leaving 664,641 shares worth $29.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2437.

Vanguard Group first reported a position in XENE in Q2 2020 and has held it in 23 quarters since. The position peaked at $34.2M in Q3 2025. 246 funds tracked by Wall St. Rank hold XENE as of Q4 2025.

  • Vanguard Group held 664,641 shares of Xenon Pharmaceuticals worth $29.8M as of Q4 2025.
  • Vanguard Group sold 186,745 Xenon Pharmaceuticals shares in Q4 2025, an estimated $7.84M.
  • Xenon Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2437 holding.
  • Vanguard Group first reported a position in Xenon Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • Vanguard Group's Xenon Pharmaceuticals position peaked at $34.2M in Q3 2025.
  • 246 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.